Podcast

The Breasties: Igniting Strength and Positivity Through Community

This week on the “CURE Talks Cancer” podcast, we discuss the power of community with The Breasties co-founders Brianna Majsiak and Allie Brudner Brumel and how their own experiences with breast cancer brought them together.

Younger people who develop breast cancer sometimes find that there are few resources for patients with cancer their age, and that treatment for breast cancer can be an isolating experience. When the founders of the Breasties faced those problems, they started an organization that brings younger people and their loved ones together for support and community when they need it most.

This week on the “CURE Talks Cancer” podcast, we spoke with two of the group’s founders, Brianna Majsiak and Allie Brudner Brumel, about how their journey brought them together, and how the Breasties makes a difference in the lives of patients, survivors, caregivers and anyone else who is touched by cancer or other reproductive-related illnesses.

As Brudner Brumel says: “Anyone who feels aligned with our mission and who feels like a Breastie is a Breastie. We don't want anyone to feel isolated. And so, if the Breasties can be that place for you, you’re a Breastie!”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Related Content